|

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

RECRUITINGPhase 3Sponsored by Vergent Bioscience, Inc.
Actively Recruiting
PhasePhase 3
SponsorVergent Bioscience, Inc.
Started2026-03
Est. completion2026-12
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations5 sites

Summary

This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging in participants undergoing surgery for cancer in the lung. Approximately 132 partiipants will be enrolled to ensure a minimum of 115 evaluable participants receiving abenacianine and undergoing NIR imaging and a control group of 12 participants who will receive abenacianine but no NIR imaging.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Be willing and able to sign the informed consent and comply with study procedures.
2. Be at least 18 years of age.
3. Be scheduled for or planning to have a surgical resection of a lung lesion or mass with diagnostic and/or curative intent.
4. Meet all requirements for the planned surgery based on opinion of the surgeon, anesthesiologist, and/or other consulting physician.
5. Be able to meet the following conditions:

   1. Female participants must be of non-childbearing potential, or,
   2. If of childbearing potential, be non-pregnant or non-lactating and agree to use highly effective contraception from screening through Day 30 after treatment.
   3. Male participants, if not surgically sterilized, and if engaging in sexual intercourse with a female partner of childbearing potential, must be willing to use highly effective contraception from screening through 30 days after dosing.
6. Have not participated in an interventional clinical trial within the last 30 days.

Exclusion Criteria:

1. They have a known allergy or reaction to radiographic contrast agents, ICG, or any component of abenacianine.
2. They have received chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to study enrollment.
3. They have any other co-morbidity or habit that the Investigator believes will interfere with their ability to comply with and complete the study. They are not a candidate for standard of care surgery based on opinion of the surgeon, anesthesiologist, or other consulting physician.
4. They are prisoners, institutionalized individuals, or are unable to consent for themselves.

Conditions3

CancerLung CancerLung Metastases

Interventions1

Locations5 sites

California

1 site
City of Hope National Medical Center
Duarte, California, 91010
Jae Kim, MD

Florida

1 site
Orlando Health Cancer Center
Orlando, Florida, 32806
Luis Herrera, MD

Minnesota

1 site
Mayo Clinic
Rochester, Minnesota, 55905
Janani Reisenauer, MD

Pennsylvania

1 site
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104
Sunil Singhal, MD

Texas

1 site
University of Texas, MD Anderson Cancer Center
Houston, Texas, 77030
David Rice, M.B., B.CH, B.A.O, F.R.C.S.I

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.